Nu-Med Competitors

OTC Stocks . USA . 
Stock . Nu Med Plus
NUMD Stock  USD 0.01  0.01  29.00%   
Nu Med Plus competes with Talis Biomedical, USA Equities, and Kelyniam Global; as well as few others. The company conducts business under Healthcare sector and is part of Medical Devices industry. Analyzing Nu-Med Plus competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nu-Med Plus to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Nu-Med Plus Correlation with its peers.

Nu-Med Plus vs Cryomass Technologies Correlation

Poor diversification

The correlation between Nu Med Plus and CRYM is 0.62 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Nu Med Plus and CRYM in the same portfolio, assuming nothing else is changed.

Moving against Nu-Med OTC Stock

  0.64WF Woori Financial Group Earnings Call This WeekPairCorr
  0.5DXCM DexCom Inc Earnings Call TomorrowPairCorr
  0.43MDT Medtronic PLCPairCorr
  0.4SHG Shinhan Financial Earnings Call This WeekPairCorr
  0.4KB KB Financial Group Earnings Call This WeekPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.018.63
Details
Intrinsic
Valuation
LowRealHigh
0.000.018.63
Details
Naive
Forecast
LowNextHigh
0.00010.018.62
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.010.020.03
Details

Nu-Med Plus Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nu-Med Plus and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Nu-Med and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nu Med Plus does not affect the price movement of the other competitor.

High positive correlations

USAQ
+ 0.82
TLIS
MSIU
+ 0.78
TLIS
USAQ
+ 0.77
PLLWF
MSIU
+ 0.72
USAQ
BNVIF
+ 0.57
USAQ
TLIS
+ 0.53
PLLWF
  

High negative correlations

CRYM
- 0.91
TLIS
CRYM
- 0.87
USAQ
CRYM
- 0.71
MSIU
MSIU
- 0.64
KLYG
CRYM
- 0.61
PLLWF
CRYM
- 0.52
BNVIF

Risk-Adjusted Indicators

There is a big difference between Nu-Med OTC Stock performing well and Nu-Med Plus OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nu-Med Plus' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PLLWF  33.36  14.77  0.00 (2.31) 0.00 
 0.00 
 0.00 
 0.00 
 644.63 
TLIS  2.31  1.21  0.00 (1.00) 0.00 
 0.00 
 0.00 
 0.00 
 77.50 
USAQ  10.29  3.19  0.26 (0.82) 7.22 
(17.59)
 34.38 
(14.71)
 79.51 
CSSI  86.55  42.20  1.65  1.04  16.59 
(176.47)
 73.91 
(35.94)
 2,704 
RHEP  3.26  0.24  0.04 (3.71) 4.02 
(4.55)
 9.49 
(8.76)
 30.85 
RQHTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
KLYG  5.60  0.00  0.00  0.05  0.00 
 0.00 
 16.67 
(15.38)
 48.89 
BNVIF  23.90  10.94  0.00  0.98  0.00 
 0.00 
 0.00 
 0.00 
 844.44 
MSIU  2.45  1.17  0.00  0.62  0.00 
 0.00 
 0.00 
 0.00 
 50.00 
CRYM  1.79 (0.89) 0.00  1.28  0.00 
 0.00 
 0.00 
 0.00 
 60.00 

Nu-Med Plus Competitive Analysis

The better you understand Nu-Med Plus competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nu-Med Plus' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nu-Med Plus' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NUMD PLLWF TLIS USAQ CSSI RHEP RQHTF KLYG BNVIF MSIU
 29.00 
 0.01 
Nu-Med
 0.00 
 0.01 
Polarean
 0.00 
 2.84 
Talis
 20.59 
 0.82 
USA
 50.00 
 0.12 
Costas
 4.62 
 1.36 
Regional
 0.00 
 0.01 
Reliq
 7.14 
 0.13 
Kelyniam
 0.00 
 0.0005 
Binovi
 0.00 
 0.0004 
Medical
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Dangerous
Out of control
Very steady
Extremely Dangerous
Very steady
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Weakest
Good
Fair
Solid
Weakest
Soft
Weakest
Weakest
Fair
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Average
Strong
Small
Hazard
Unknown
High
Small
Low
Strong
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Hold
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Current Ratio
0.03
10.43
12.51
0.22
0.04
N/A
4.61
0.77
0.57
0.13
Net Asset
22.16 K
34.53 M
98.34 M
2.21 M
1.52 M
N/A
10.27 M
N/A
12.3 M
1.27 M
Profit Margin
N/A
N/A
N/A
-0.8
N/A
N/A
-0.39
-0.0522
N/A
-1.73
EBITDA
(808.68 K)
(13.38 M)
(60.7 M)
(487.63 K)
(272.74 K)
N/A
(8.02 M)
30.35 K
(8.2 M)
(456.42 K)
Current Valuation
1.63 M
114.3 M
(38.24 M)
2.88 M
903.48 K
N/A
78.18 M
2.09 M
576.69 K
2.13 M
Price To Book
49.86
4.81
0.0581
5.21
N/A
N/A
16.65
N/A
0.0771
N/A
Operating Margin
N/A
-11.27
-113.6
-0.4
-3.85
N/A
-0.45
-0.0053
-15.09
-1.77
Retained Earnings
(2.41 M)
N/A
(539.96 M)
N/A
(314 K)
N/A
N/A
N/A
N/A
N/A
Current Asset
57.17 K
N/A
N/A
N/A
200 K
N/A
N/A
N/A
N/A
N/A
Beta
0.52
0.67
1.62
-3.6
2.56
N/A
1.52
-1.08
0.39
366.91
Number Of Employees
2
28
99
5
3
N/A
13
12
5
N/A
Shares Outstanding
81.35 M
213.05 M
1.82 M
9.32 M
14.29 M
N/A
196.76 M
N/A
26.61 M
25.51 M
Cash Flow From Operations
(206.83 K)
(12.25 M)
(53.24 M)
(354.74 K)
223
N/A
(8.03 M)
140.9 K
(6.07 M)
(323.1 K)
Total Debt
2.06 K
430.26 K
19.67 M
502.96 K
60.95 K
N/A
40 K
381.96 K
34.43 K
1.21 M
Return On Equity
-545.23
-0.49
-0.7
-2.41
N/A
N/A
-0.65
-0.22
-0.72
N/A
Z Score
38.4
N/A
N/A
1.2
1.2
N/A
N/A
7.2
28.8
N/A
Return On Asset
-6.62
-0.27
-0.3
-0.14
N/A
N/A
-0.29
-0.007
-0.31
-0.32
Book Value Per Share
-0.003
0.12
26.68
0.031
-0.001
N/A
0.043
0.025
0.59
-0.03
Number Of Shares Shorted
N/A
N/A
17.96 K
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Liabilities
490.62 K
N/A
N/A
N/A
134 K
N/A
N/A
N/A
N/A
N/A
Total Asset
22.16 K
34.53 M
98.34 M
2.21 M
1.52 M
N/A
10.27 M
N/A
12.3 M
1.27 M
Debt To Equity
0.037
0.016
0.19
3.46
0.33
N/A
0.047
0.55
0.11
N/A
Target Price
N/A
1.0
5.0
5.0
N/A
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
N/A
0.59
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
32.42
52.15
3.87
N/A
N/A
0.01
N/A
N/A
N/A
Market Capitalization
1.14 M
125.73 M
7.98 M
1.24 M
140 K
N/A
73.78 M
4.59 M
1.65 M
5.1 K
Price To Earning
19.0
N/A
N/A
-0.06
5.0
N/A
-7.07
12.86
N/A
-3.25
Price To Sales
N/A
97.91
19.57
1.18
N/A
N/A
6.99
1.24
3.86
0.15
Net Income
(830.06 K)
(14.02 M)
(62.01 M)
(770.18 K)
(66.51 K)
N/A
(8.17 M)
201.74 K
(9.03 M)
(627.33 K)
Earnings Per Share
-0.007
-0.071
-28.02
-0.1
-0.078
N/A
-0.039
0.007
-0.39
-0.034
Shares Owned By Insiders
61.99
25.95
8.3
35.98
69.92
N/A
1.76
N/A
5.93
N/A
Revenue
N/A
1.19 M
412 K
1.41 M
N/A
N/A
8.55 M
2.91 M
728.48 K
362.07 K
Working Capital
(433.44 K)
N/A
68.91 M
N/A
66 K
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
2.54 K
22.69 M
165.37 M
97.17 K
4.94 K
N/A
890.15 K
672
1.02 M
23.38 K
Cash Per Share
N/A
0.11
6.21
0.01
N/A
N/A
N/A
N/A
0.04
N/A
Gross Profit
N/A
508.02 K
(149.4 M)
670.75 K
N/A
N/A
5.3 M
2.05 M
440.89 K
(10.85 K)
Day Typical Price
0.0142
0.0066
2.84
0.79
0.097
1.34
0.01
0.13
5.0E-4
4.0E-4
Accumulation Distribution
N/A
N/A
N/A
175.24
0.58
183.4
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
N/A
N/A
1.0E-4
0.069
0.0
N/A
N/A
N/A
N/A
Daily Balance Of Power
0
0.0
0.0
1.4
0.5797
1.0
0.0
0
0.0
0.0
Period Momentum Indicator
(0.01)
N/A
N/A
0.14
0.04
0.06
N/A
(0.01)
N/A
N/A
Rate Of Daily Change
0.71
1.0
1.0
1.21
1.5
1.05
1.0
0.93
1.0
1.0
Day Median Price
0.0142
0.0066
2.84
0.77
0.0855
1.33
0.01
0.13
5.0E-4
4.0E-4
Price Action Indicator
(0)
N/A
N/A
0.12
0.0545
0.06
N/A
(0.01)
N/A
N/A
Relative Strength Index
29.87
67.54
100.0
59.9
68.04
53.02
N/A
45.83
62.78
100.0
Coefficient Of Variation
(1,070)
681.2
812.4
489.96
742.39
2001.97
N/A
(27,707)
862.25
581.66
Mean Deviation
3.38
33.36
2.31
10.29
86.55
3.26
N/A
5.6
23.9
2.45
Jensen Alpha
(0.81)
14.77
1.21
3.19
42.2
0.2388
N/A
(0)
10.94
1.17
Total Risk Alpha
(1.29)
8.71
0.6054
2.16
24.87
(0.05)
N/A
(0.60)
5.66
0.8224
Sortino Ratio
N/A
N/A
N/A
0.2615
1.65
0.0361
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
130.86
711.68
28.57
N/A
N/A
N/A
N/A
Standard Deviation
8.42
98.84
9.54
14.92
326.85
4.93
N/A
9.49
98.71
7.34
Kurtosis
14.64
29.35
66.0
2.69
64.53
2.85
N/A
1.85
65.58
35.72
Potential Upside
N/A
N/A
N/A
34.38
73.91
9.49
N/A
16.67
N/A
N/A
Treynor Ratio
(2.17)
(2.31)
(1.00)
(0.82)
1.04
(3.71)
N/A
0.046
0.9802
0.6176
Maximum Drawdown
72.68
644.63
77.5
79.51
2704.36
30.85
N/A
48.89
844.44
50.0
Variance
70.86
9770.2
91.0
222.49
106828.3
24.28
N/A
90.08
9743.47
53.94
Market Risk Adjusted Performance
(2.16)
(2.30)
(0.99)
(0.81)
1.05
(3.70)
N/A
0.056
0.9902
0.6276
Risk Adjusted Performance
(0.06)
0.1177
0.0996
0.1593
0.1089
0.0452
N/A
0.0066
0.0951
0.1352
Skewness
1.48
5.46
8.12
1.47
7.99
0.4473
N/A
(0.19)
8.08
5.95
Semi Deviation
N/A
N/A
N/A
7.22
16.59
4.02
N/A
N/A
N/A
N/A
Information Ratio
(0.1)
0.1463
0.1175
0.2005
0.1345
0.0392
N/A
(0.01)
0.1154
0.1647
Value At Risk
(13.33)
N/A
N/A
(14.71)
(35.94)
(8.76)
N/A
(15.38)
N/A
N/A
Expected Short fall
N/A
N/A
N/A
(17.59)
(176.47)
(4.55)
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
11.44
26.68
5.34
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
52.1
275.22
16.17
N/A
N/A
N/A
N/A

Nu-Med Plus Competition Performance Charts

Five steps to successful analysis of Nu-Med Plus Competition

Nu-Med Plus' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nu Med Plus in relation to its competition. Nu-Med Plus' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nu-Med Plus in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nu-Med Plus' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nu Med Plus, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nu-Med Plus position

In addition to having Nu-Med Plus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Technology Thematic Idea Now

Technology
Technology Theme
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Nu-Med OTC Stock

Nu-Med Plus financial ratios help investors to determine whether Nu-Med OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nu-Med with respect to the benefits of owning Nu-Med Plus security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY